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Abstract: Bronchopulmonary dysplasia (BPD) remains the most common severe complication of
preterm birth, and nutrition plays a crucial role in lung growth and repair. A practical nutritional
approach for infants at risk of BPD or with established BPD is provided based on a comprehen-
sive literature review. Ideally, infants with BPD should receive a fluid intake of not more than
135–150 mL/kg/day and an energy intake of 120–150 kcal/kg/day. Providing high energy in low
volume remains a challenge and is the main cause of growth restriction in these infants. They need
a nutritional strategy that encompasses early aggressive parenteral nutrition and the initiation of
concentrated feedings of energy and nutrients. The order of priority is fortified mother’s own milk,
followed by fortified donor milk and preterm enriched formulas. Functional nutrient supplements
with a potential protective role against BPD are revisited, despite the limited evidence of their
efficacy. Specialized nutritional strategies may be necessary to overcome difficulties common in
BPD infants, such as gastroesophageal reflux and poorly coordinated feeding. Planning nutrition
support after discharge requires a multidisciplinary approach to deal with multiple potential prob-
lems. Regular monitoring based on anthropometry and biochemical markers is needed to guide the
nutritional intervention.
Keywords: bronchopulmonary dysplasia; enriched formulas; fluid restriction; growth monitoring;
human milk fortification; preterm infants
1. Introduction
Bronchopulmonary dysplasia (BPD), also named chronic lung disease of prematurity,
is a lung disease that causes dependence on oxygen for an extended period of time [1–3].
The “new BPD” seen today results from a reparative process in alveolar and vascular
compartments of the lung, after injury caused by ante- and postnatal pathogenic factors
leading to reduced, large, thin-walled alveoli, and less fibrosis when compared to the
“old BPD” [2].
The definition of BPD has been a challenging issue. In 2001, a workshop sponsored by
the National Heart, Lung, and Blood Institute defined BPD as the persistence of oxygen
requirement at 28 days of life and 36 weeks postmenstrual age (PMA) [4]. A more recent
Eunice Kennedy National Institute of Child Health and Human Development workshop
proposed some refinements to the 2001 definition of BPD [5].
The overall incidence of BPD in infants delivered below 28 weeks’ gestational age is
about 30–68% and is inversely proportional to the gestational age [6]. The large variability
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in rates among centers is partially related to differences in clinical practices, such as the
criteria used for the management of mechanical ventilation [7].
BPD remains the most common severe complication of preterm birth and is char-
acterized by a high grade of inflammation of the immature lung [8,9]. It represents a
major challenge for neonatologists who deal with modifiable risk factors for BPD devel-
opment, including surfactant replacement therapy, ventilation strategies, corticosteroids,
inhaled nitric oxide, inhaled bronchodilators, and macrolides [10,11]. Among postnatal
factors, nutrition plays a central role in lung growth and repair [1,12,13]. Nevertheless,
it should be kept in mind that malnutrition may start in intrauterine life, constituting an
important prenatal risk factor for BPD [14–18]. After preterm birth, several problems
associated with extreme immaturity result in difficulty in achieving sufficient energy and
nutrient intake [19]. A recent study by Milanesi et al. [20] found that preterm infants
who developed BPD, compared with those without BPD, received an energy/protein ratio
below what is recommended. A retrospective cohort study reported that, in extremely
preterm infants, high fluid intake containing low energy during the first postnatal week is
associated with the severity of BPD [20]. Along the same lines, other studies have described
the association of postnatal deficit in energy and nutrient and postnatal growth restriction
with the development of BPD [21–24].
2. Aim
This narrative review aimed to gather evidence on the nutritional support of preterm
infants with increased risk for BPD, or with established BPD, in order to provide data to
optimize their nutritional approach.
3. Literature Search
An extensive search in the databases of medical literature, including Pubmed/Medline,
Scielo, Medscape, Cochrane Database of Systematic Reviews, Cinahl Complete, and Clini-
calTrials.gov, was performed, including the years from 1980 to 2021 as well as information
available from Google. The terms “antioxidants”, “bronchopulmonary dysplasia”, “chronic
lung disease”, “enteral nutrition”, “functional nutrients”, “morbidity”, “nutritional man-
agement”, “parenteral nutrition”, “prematurity”, and “preterm infant” were used for
the search.
4. Fluid Management in Infants at Risk for and with Established BPD
Preterm neonates with risk factors for the development of BPD should be consid-
ered high-risk infants. Compared to full-term neonates, very low birth weight (VLBW)
and extremely low birth weight (ELBW) infants have a higher proportion of body water,
more immature renal function, and a limited capacity to eliminate excess of fluids [25].
A physiological contraction of extracellular fluid, with a negative water and sodium balance,
occurs during the first postnatal week [25]. Excessive fluid intake will impair this physio-
logical mechanism and is associated with a significant risk of hemodynamically significant
patent ductus arteriosus [26]. Moreover, an early fluid overload (150–190 mL/kg/day) [27]
may cause pulmonary edema, with reduction of lung compliance, increased airway resis-
tance, and the need for more aggressive respiratory support [28–30].
In a retrospective cohort study of ELBW infants, it was found that high fluid intake
during the first postnatal week and lack of physiological weight loss in the first 10 postnatal
days were associated with an increased risk of BPD [31]. A meta-analysis of randomized
controlled studies determining the effect of fluid intake on morbidities and mortality
in premature infants concluded that the risk of BPD was not significantly affected by
water intake, although fluid restriction was associated with a trend toward reduced risk
of BPD [31]. Thus, it seems prudent to employ a strategy of fluid restriction in preterm
infants considered to be at high risk for BPD. A reasonable approach is to start with
fluid intake not exceeding 80–100 mL/kg in the first postnatal day, with a subsequent
progressive increase, up to a maximum of 135–150 mL/kg/day [31–33]. In infants with
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established BPD, a restriction of 135 mL/kg/day, or less, may be necessary in severe
cases [31,32,34]. In this regard, fluid restriction should be within the clinically acceptable
limits of fluid intake, since reduction of free water intake may lead to an increase in renal
solute load with the risks of renal dysfunction and nephrocalcinosis [33]. When fluid
restriction is prescribed, evaluation of net fluid balance is mandatory, which includes the
monitoring of body weight, urine output, plasma sodium, blood pressure, and functional
echocardiographic assessment [33,34].
Body temperature and environmental humidity influence the fluids policy [35–39].
The temperature of the abdominal skin should be kept between 36.0 ◦C and 36.5 ◦C,
and the inspired air temperature (hood, CPAP, or ventilator) between 34.0 ◦C and 41.0 ◦C
at the Y-piece, with a relative humidity of 100% [35–39]. A survey on incubator humidity
practices in the management of preterm infants found a wide variation in humidification
practices, but the majority of the surveyed centers used a starting humidity higher than
80% [38]. A systematic review including 12 studies assessing preterm infants’ outcomes
related to incubator humidity concluded that 60–70% humidity in the first postnatal week
was enough to reduce the transepidermal water loss in infants born at 26 weeks or older;
however, more research is needed regarding more immature infants [37].
Phototherapy may increase insensible water loss and addition of 10–20 mL/kg/day
to the total fluids may be needed, although this seems unnecessary when using the newer
phototherapy lamps with light-emitting diodes [40].
5. Nutritional Requirements in Infants with BPD
Nutrition plays a critical role in the prevention and management in infants with
BPD, and a vicious cycle may occur. Growth failure in BPD infants is predominantly due
to malnutrition. Malnutrition, in turn, seems to worsen BPD probably by compromis-
ing lung development and function, and feeding difficulties in these infants can further
affect nutrition [12,41].
As BPD is not typically diagnosed until 28 days of life or 36 weeks PMA, attempts to
prevent postnatal growth failure cannot be made soon enough, as this condition can result
in nutrient deficits that may be difficult to recover from [12].
In BPD infants, a status of increased respiratory work and inflammatory response,
along with the lung damage/repair process, is characterized by higher energy consump-
tion [35]. This energy should be provided in restricted fluid intake, since fluid overload
may cause pulmonary edema, which can decrease lung compliance and increase airway
resistance [14].
Uberos et al. [41], in a cohort study, found that infants who developed BPD, compared
with those who did not, received a lower total intake of energy (76.1 vs. 91.1 kcal/kg/day),
carbohydrate (11.6 vs. 12.6 g/kg/day), and fat (2.5 vs. 3.4 g/kg/day) during the first
14 days of life. Klevebro et al. [42] examined the effect of early nutritional intake on growth
and the risk of BPD in 296 extremely preterm infants and found that, between days 7 and
27, every additional 10 kcal/kg/day in energy intake was associated with a 9% reduction
in the risk of BPD.
Improved nutritional strategies have enhanced postnatal growth in infants at high risk
of growth restriction [43]. Nevertheless, the optimal energy intake for children at risk of
BPD or with established BPD is still to be defined. It seems that infants with confirmed BPD
should receive an energy intake in a range of 120–150 kcal/kg/day and a protein intake of
at least 3.5 g/kg/day [44]. In infants with chronic lung disease, a high-fat diet theoretically
produces lower rates of carbon dioxide production than a diet with a lower fat and higher
carbohydrate content [45]. However, pulmonary function test results were found to be
equivalent in infants receiving high-fat or high-carbohydrate feedings [46]. In addition,
65% of nonprotein energy supplied as carbohydrate was found to be more effective than
energy supplied as fat in sparing protein oxidation in enterally fed LBW infants [47].
In healthy preterm infants receiving adequate nutrition support, an optimal weight
gain velocity of 15–20 g/kg/day is expected [48].
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6. Functional Nutrients with Potential Beneficial Effects on BPD
The preterm infant’s inability to down-regulate and maintain control of the inflam-
matory immune response may facilitate ongoing lung damage, leading to a chronic in-
flammatory state [49]. Some functional nutrients with antioxidant effects could play a
role in reducing lung inflammation [49–51]. Despite the lack or limited evidence of their
protective effect against BPD through an antioxidant effect or other mechanisms, their use
with this purpose, as supplements in parenteral and enteral nutrition, is revisited.
6.1. Polyunsaturated Fatty Acids
In a historical cohort study of preterm infants with less than 30 weeks of gestation,
a rapid decline in DHA and arachidonic acid levels in the first postnatal week, with a
concomitant increase in linoleic acid (LA) levels, was observed [52]. Increased risk of BPD
was associated with decreased DHA levels (OR 2.5; 95% CI 1.3-5.0) and increased LA:DHA
ratio (OR 8.6; 95% CI 1.4-53.1) [52]. Based on data from preterm infants and animal studies
suggesting that docosahexaenoic acid (DHA) serves as a general preventive agent against
inflammation, observational and interventional clinical studies were developed to improve
DHA delivery in preterm infants to reduce the risk of BPD [49]. In a multicenter, random-
ized controlled trial, breast milk-fed, very preterm infants with birth weight <1250 g born
to mothers who were given a high-DHA diet had a 12% decrease in the incidence of BPD
compared with infants whose mothers did not receive supplements [50]. This effect was
not observed in other clinical trials of breast milk-fed infants born at less than 29 weeks’
gestation to mothers who were given DHA during the neonatal period, compared with the
placebo. However, these results may have been affected by the early trial termination [53].
In another trial, it was reported that infants born at less than 29 weeks’ gestation and re-
ceiving enteral emulsion providing 60 mg/kg/day of DHA, from the beginning of enteral
feeding until 36 weeks PMA, did not have a lower risk of BPD than those given a control
emulsion [54]. A meta-analysis including 14 randomized controlled trials that involved
3531 preterm infants investigated the efficacy of intervention with n-3 polyunsaturated
fatty acids on the incidence of BPD and found no evidence (risk ratio 0.99; 95% CI 0.84–1.18)
to support this intervention [55]. A similar conclusion was obtained in another system-
atic review and meta-analysis of four randomized controlled trials involving 1966 very
preterm infants [56].
6.2. Amino Acids
Glutamine during oxidative stress can reduce cell injury by increasing glutathione [57].
This finding motivated supplementation of this amino acid in preterm infants. How-
ever, a meta-analysis of 11 randomized controlled trials including 2771 preterm infants
concluded that parenteral and/or enteral supplementation with glutamine did not de-
crease BPD [58].
N-acetylcysteine is a precursor of cysteine and is itself a free radical scavenger [33].
A multicenter, double-blind trial showed that a six-day course of intravenous N-acetylcysteine
infusion during the first postnatal week did not prevent BPD in ELBW infants [59].
6.3. Vitamins
Vitamin A regulates the growth and differentiation of epithelial cells in the respiratory
tract and is an important radical-scavenging antioxidant [60,61]. ELBW infants have low
plasma and tissue concentrations of vitamin A, and vitamin A deficiency may predispose to
BPD [62]. Clinical trials showed that intramuscular administration of vitamin A decreased
the risk of BPD in ELBW infants [62,63]. Based on these results, it was questioned whether
a higher dose of vitamin A supplementation might further reduce the risk of BPD [64,65].
Meanwhile, a systematic review and meta-analysis of four studies including 1011 preterm
infants concluded that vitamin A supplementation for ELBW infants benefited oxygen
dependency at 36 weeks PMA in survivors (pooled risk ratio, 0.88; 95% CI 0.77–0.99) [66].
Another systematic review and meta-analysis of three studies including 612 preterm infants
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assessing the effect of enteral vitamin A supplementation on BPD found a significant
reduction in the incidence of BPD in the vitamin A-treated group compared to placebo
(OR 0.57; 95% CI 0.24–1.35) [61].
Vitamin E is another radical-scavenging antioxidant that protects cell membranes
from oxidative injury [67]. Tocopherol deficiency worsens the effect of oxygen toxicity on
lung tissue and its supplementation may have a protective effect on premature lungs [33].
A strong correlation of BPD with low plasma vitamin E and selenium levels measured
in cord plasma and on the third postnatal day was reported in premature infants [51].
However, in preterm infants it was not demonstrated that supplemental vitamin E during
the acute phase of therapy for respiratory distress syndrome modified the development
of BPD [68].
Inositol, as a member of the vitamin B complex, is involved in surfactant synthesis
and maturation, and its serum levels are low in preterm infants [33]. A meta-analysis
evaluating the effect of inositol supplementation in preterm infants found a trend toward
the reduction of BPD at 28 days, but this did not reach statistical significance [69].
6.4. Trace Elements
Copper, zinc, selenium, and manganese act as co-factors of antioxidant enzymes,
such as the copper-zinc superoxide dismutase and manganese superoxide dismutase [33,70].
However, in ELBW infants, an association between BPD and decreased antioxidant enzyme
activities related to trace elements was not demonstrated [71].
In a prospective study including 83 preterm infants, it was found that BPD was inde-
pendently associated with significantly lower serum zinc levels at term age than those who
did not develop the disease [72]. A randomized controlled trial including 193 VLBW infants
determined the efficacy of zinc supplementation in reducing morbidity. No difference was
observed in the rate of BPD, necrotizing enterocolitis, sepsis, periventricular leukomalacia,
or retinopathy of prematurity between the group receiving zinc supplementation and that
not supplemented. However, the risk of developing at least one of these morbidities was
significantly reduced (OR 0.513; 95% CI 0.280–0.939) in the supplemented group [73].
The reduced stores of selenium in preterm infants motivated supplementation, but a
meta-analysis of three trials found no benefit of selenium supplementation in the develop-
ment of BPD [74].
7. Nutritional Approach in the Prevention and Management of BPD
Table 1 summarizes the preventive nutritional approach in infants at high risk of
BPD and Table 2 summarizes nutritional management in infants with established BPD,
using parenteral and/or enteral nutrition either in the hospital or after discharge.
Figure 1 schematically represents the nutritional approaches in infants at high risk of
BPD and with established BPD, according to the contents of Tables 1 and 2, respectively.
In the following subsections, specific adaptations of both parenteral and enteral
nutrition for infants at high risk of BPD and with established BPD are addressed.
7.1. Parenteral Nutrition
For healthy preterm infants, 90–120 kcal/kg/day of energy is recommended through
exclusive parenteral nutrition, after the first postnatal week [75,76]. BPD infants are a
special subset of preterm infants who were found to receive a lower energy intake than
those without BPD in the first month of life [77]. Therefore, in infants at high risk of BPD,
an energy intake of 80–100 kcal/kg/day should be provided in the first postnatal week,
and 120–150 kcal/kg/day between the second and fourth postnatal weeks [44,78].
In healthy preterm infants, 1.5–2.0 g/kg/day of amino acids should be provided
as soon as possible after birth, increasing to 3.5 g/kg/day for the first 48–72 postna-
tal hours [79].
Although the maximum recommended dose of glucose through parenteral nutrition
is 12 mg/kg/min, its maximum oxidation capacity is 8.3 mg/kg/min in preterm infants
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(12 g/kg/day). In infants at risk of BPD or with established BPD, the administration of
high doses of glucose can cause excessive carbon dioxide production [78].
Figure 1. Preventive nutritional approach in infants at high risk of BPD and nutritional management
in infants with established BPD. BPD: bronchopulmonary dysplasia.
To meet the recommended energy intake, intravenous lipids are a good source of
energy and essential fatty acids [80]. In addition, the administration of lipids to critically ill
patients decreases the de novo lipogenesis from glucose and carbon dioxide production [80].
In healthy preterm infants, it is recommended to start at 1.0–2.0 g/kg/day within the first
24 postnatal hours, with an increase of 0.5–1.0 g/kg/day up to a maximum of 4.0 g/kg/day
from 72–96 postnatal hours [80]. A minimum of 1.0 g/kg/day of parenteral lipids is
recommended to avoid a deficit in essential fatty acids [80]. The current 20% intravenous
fat emulsions (IVFEs) containing soybean oil, medium-chain triglycerides (MCT), and/or
fish oil are a good option for the more complete supply of essential fatty acids to preterm
infants [81,82]. In addition, new-generation IVFEs, particularly those rich in MCT and
fish oil, were reported to reduce lipid peroxidation, oxidative stress, and inflammatory
response due to their high n-3 polyunsaturated fatty acid content and low content of n-6
fatty acids [83]. Theoretically, the composition of new-generation IVFEs could alleviate
inflammation in preterm infants receiving parenteral nutrition and reduce morbidities such
as BPD [82]. However, a systematic review and meta-analysis that included 22 studies and
involved 3781 preterm infants, determining the associations of different IVFEs with the
occurrence of BPD, found no evidence that the new-generation IVFEs could prevent BPD,
including those containing fish oil [81].
In a prospective study examining 135 preterm infants weighing less than 1250 g,
those with BPD had a suboptimal bone growth and a higher incidence of metabolic bone
disease [77]. This was due to a nutritional deficit in calcium and phosphorus rather than
problems with vitamin D metabolism [77]. On the other hand, chronic use of diuretics to
reduce fluid overload in BPD increased the urinary loss of calcium [84]. Hydrochloroth-
iazide is preferred due to its calcium-sparing effect compared with furosemide [84,85].
Recently, doses of calcium and phosphate provided through PN were reviewed and
much higher doses were recommended than previously: in the first postnatal week Ca
32–80 mg/kg/day and P 31–62 mg/kg/day; subsequently, Ca 100–140 mg/kg/day and P
77–108 mg/kg/day, with a Ca/P ratio of 1.3 (mass) or 1 (molar) [76,86]. These very high
doses are difficult to achieve in infants with BPD due to fluid restriction and the inherent
risk of calcium phosphate precipitation in parenteral nutrition solutions [87,88]. During the
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first postnatal days, it seems prudent not to exceed concentrations of Ca and P of 68 mg/dL
and 52.7 mg/dL, respectively [89].
Adequate doses of vitamins should be provided through parenteral nutrition, since
preterm infants are especially prone to vitamin deficits due to their limited stores and rapid
growth rate [76,90]. As mentioned before, a deficit of some vitamins in preterm infants was
associated with the risk of BPD [33,51,62].
Trace elements such as zinc, copper, manganese, chromium, selenium, and molyb-
denum are also currently recommended in neonatal long-term parenteral nutrition, in-
cluding in infants with BPD, since some of them are important co-factors of antioxidant
enzymes [70,76,91].
7.2. Enteral Nutrition While in the Hospital
7.2.1. Enteral Nutrition Recommendations
A fluid intake of 135 mL/kg/day is considered the minimum enteral volume to supply
sufficient energy and nutrients in healthy preterm infants [92], and this is the maximum
fluid intake tolerated by many infants with established BPD [32,34].
It is estimated that infants with BPD require 15–25% more energy than those without
BPD [57]. An energy intake in the range of 120–150 kcal/kg/day is needed in BPD
infants [44], although a minimum of 140 kcal/kg/day may be necessary during active
periods of the disease [57,93]. Providing such high-energy intake in low volumes of feeds
remains a challenge and requires concentrating energy and macronutrients [20,23].
In a cohort study assessing the nutritional supply in very preterm infants, those who
developed BPD received an energy intake and energy/protein ratio below that recom-
mended for growth [20]. In line with these results, in a retrospective case–control study,
it was found that extremely preterm infants with BPD received lower energy and fluid
intake during the first month of life, and a lower four-week averaged daily energy intake
was an independent predictor for BPD [23].
From the scarce randomized trials demonstrating the efficacy of nutritional interven-
tions in the prevention or treatment of BPD, the interventional cohort study by Gianni
et al. [44] showed that in very preterm infants with BPD, a greater protein/energy supply
allowed for faster weight gain than in a historical cohort.
As few studies have evaluated the protein needs of infants with BPD, it may be
appropriate to assume that these are comparable to the needs of preterm infants without
BPD. The ESPGHAN recommends enteral protein intakes of 3.5–4.0 g/kg/day for infants
weighing 1000–1800 g and 4.0–4.5 g/kg/day for those with less than 1000 g [92].
Fat is a good source of nonprotein energy when it is necessary to provide high energy
intake in a low volume of feedings [93,94]. For preterm infants with BPD, fat provides
essential fatty acids and lipid soluble vitamins, and its oxidation produces less carbon diox-
ide [92]. An enteral intake of 4.8–6.6 g/kg/day of lipids, including 385–1540 mg/kg/day
of LA and more than 50 mg/kg/day of α-linolenic acid, is recommended for healthy,
growing preterm infants [92].
Long-term use of steroids and loop diuretics and limited mineral intake due to
fluid restriction are recognized additional risk factors for metabolic bone disease in in-
fants with BPD [95]. However, the ability of VLBW infants with early BPD to grow
and accrete calcium was reported to be similar to that of those without early BPD [96].
Providing in a low volume of feedings the high intakes of Ca (120–140 mg/kg/day)
and P (60–90 mg/kg/day) recommended by the European Society for Paediatric Gas-
troenterology Hepatology and Nutrition (ESPGHAN) [92] or the even higher intakes
of Ca (150–220 mg/kg/day) and P (75–140 mg/kg/day) recommended by the Ameri-
can Academy of Pediatrics is challenging [97]. For healthy preterm infants, the recom-
mended intake of magnesium is 8–15 mg/kg/day [92] and that of vitamin D varies from
400–1000 IU/day [98] to 800–1000 IU/day [92].
In a single-center study including 243 infants of less than 32 weeks’ gestation, the in-
cidence of anemia was higher in BPD infants than non-BPD infants, and the number
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of transfusions was a significant risk factor for BPD [99]. Therefore, prevention and
treatment of early anemia are necessary, and reducing the number of transfusions may
reduce the incidence of BPD in preterm infants [99]. For preterm infants, iron supple-
mentation at 2–4 mg/kg/day from 4–8 postnatal weeks to 12–15 months of life has been
suggested [100,101].
Prolonged diuretics use to manage fluid balance in infants with BPD may cause
hyponatremia, requiring sodium supplementation to maintain the sodium stores necessary
for optimal growth [12]. In a retrospective study including 340 very preterm infants, it was
found that severe late-onset hyponatremia (<130 mEq/L) affected the development of BPD
(OR 2.95; 95% CI 1.06–8.24), despite not affecting growth beyond the neonatal period [102].
7.2.2. Type of Feedings
Human Milk
Mother’s own milk (MOM) is the first choice for feeding healthy preterm infants due to its
unique nutritional and biological properties. When MOM is not available, pasteurized donor
human milk (DHM) is the second choice if human bank milk is available [19,101].
A systematic review and meta-analysis gathering 22 observational and interventional
studies and involving 8661 preterm infants evaluated the effects of human milk (HM) on the
risk of BPD and concluded that both exclusive and partial HM feeding were associated with
lower risk of BPD, although the quality of evidence was low [103]. It is well known that HM
has nutritional and bioactive components, including cytokines, antioxidants, lactoferrin,
lysozymes, secretory immunoglobulin A, and growth factors that counteract oxidative
stress and inflammation [104,105]. However, it is not yet known which components can
exert a protective effect against BPD.
Some systematic reviews and meta-analyses have assessed specifically the associ-
ation between feeding with MOM, DHM, or formula and the risk of BPD. Villamor-
Martínez et al. [106], in a systematic review and meta-analysis of 15 studies involving 4984
very preterm infants (1416 BPD cases), assessed whether MOM could protect from BPD.
They concluded that MOM could reduce the incidence of BPD (RR 0.74; 95% CI 0.57–0.96,
five studies) when used as an exclusive diet. These results should be interpreted with
caution since the analysis was not adequately powered to detect changes in BPD rates and
adjust for confounders [106]. Based on another systematic review and a meta-analysis of
18 studies including very preterm infants, the same authors concluded that DHM also
protects against BPD [107]. Specifically, the supplementation with DHM reduced BPD
(RR 0.78; 95% CI 0.67–0.90, eight studies), as it happened with an exclusive HM diet
compared with a preterm formula and/or a bovine milk-based fortifier (RR 0.80; 95% CI
0.68–0.95, three studies) [107]. Feeding raw MOM compared with pasteurized MOM pro-
tected against BPD (RR 0.77; 95% CI 0.62–0.96, two studies) [106]. In contrast, another
systematic review and meta-analysis examining the effect of HM on morbidity of VLBW
infants did not find conclusive evidence for the effect of exclusive HM feeding on BPD
versus exclusive preterm formula feeding [108].
To prevent nutritional insufficiencies of HM while taking advantage of its biological
properties, HM multinutrient fortifiers were conceived for HM-fed preterm infants [109].
Using the standard fortification method, a fixed dose of fortifier is added to HM, not tak-
ing into account the great variability in its nutritional composition [110]. In consequence,
poor nutritional support due to the overestimation of the energy and macronutrient content
of HM associated with suboptimal growth and adiposity were reported in growing preterm
infants [111,112]. To overcome the problems inherent in standard fortification, alternative
individualized HM fortification methods have been proposed, particularly adjusted fortifi-
cation and target fortification [113]. In adjusted fortification, a modular protein supplement
is added to fortified HM, oriented by blood urea nitrogen (BUN) as an indicator of the in-
fant metabolic response [114]. The target fortification is based on the regular measurement
of the energy and macronutrient contents of HM, in order to customize the target energy
and macronutrients to each infant [115]. To achieve the desirable nutrient targets, modu-
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lar supplements of protein, carbohydrate, and fat may further be added to the fortified
HM [101,114–116]. In an interventional cohort study, the target HM fortification resulted in
improved weight gain velocity in BPD infants [44]. In order to comply with the ESPGHAN
enteral nutrition recommendations for preterm infants [92], the target fortification seems
an attractive and precise method to customize energy and macronutrient in HM-fed infants
with BPD subjected to fluid restriction. However, the target HM fortification requires an
HM analyzer that is not available in most neonatal units [117].
Supplementation with multivitamin and iron is recommended for HM-fed infants,
even when fortified HM is used [27]. In a retrospective cohort study in ELBW infants, zinc
supplementation improved growth in HM-fed infants with BPD [118].
Preterm Formulas
When HM is insufficient or unavailable, healthy preterm infants should be fed preterm
formulas while in the hospital [19,119]. These enriched formulas containing high energy
and protein densities are of particular use in fluid-restricted infants with BPD [120].
Preterm formulas are advantageous since their high nutrient density and sources
of macronutrients match the nutritional needs and digestive capacity of preterm infants,
compared with formulas conceived for term infants [19,121]. In particular, preterm formu-
las contain extra energy, protein, calcium, and phosphorus, and the fat source is a blend
of vegetable oils containing long-chain triglycerides and MCT [121]. In preterm infants,
MCT have the theoretical advantage of allowing for a better capacity for lingual and gastric
lipases to hydrolyze fatty acids of medium carbon chain length, not requiring a large bile
salt pool for their absorption, and being potentially better for energy production than
longer-chain fatty acids [21,122].
In some BPD infants with worse pulmonary function requiring greater fluid restric-
tion, some authors have proposed increasing the energy and macronutrient intake by
adding modular supplements of protein, carbohydrate, and fat to enriched formulas [123].
This formula manipulation has the inherent risks of increasing the osmolality of feedings
and compromising the energy/protein ratio [124].
Infants with BPD with early signs of metabolic bone disease of prematurity should
receive extra calcium, phosphorus, and vitamin D, provided by fortified HM or preterm
formula [33].
7.2.3. Timing of Initiation
For healthy preterm infants, the ESPGHAN recommends to start feeding with minimal
enteral nutrition or trophic feeding, defined as the supply of nutritionally insignificant
milk volumes of 12–24 mL/kg/day to maintain intestinal integrity [125].
The timing of initiation of enteral feeding may have an impact on intestinal inflam-
mation and risk of neonatal comorbidities. In a retrospective cohort study of 133 infants
born at less than 33 weeks of gestation, the effect of the timing of the first enteral feeding
on the inflammatory state of the intestinal tract and risk of neonatal morbidities was eval-
uated [126]. Late enteral feeding, which was considered the initial enteral feeding after
the third postnatal day, was associated with increased fecal IL-8 levels and a decreased
IL-10:IL-8 ratio [126]. After multivariate analysis, late enteral feeding was found to be
associated with a 4.5-fold increase of BPD (95% CI 1.8–11.5; p = 0.002) [126]. These results
are consistent with a secondary analysis of a prospective multicenter cohort study, in which
elevated circulating IL-8 levels were found in 606 ELBW infants who developed BPD
or died [127].
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Table 1. Preventive nutritional approach in infants at high risk of BPD.
Intervention Reference
Avoid excessive fluid intake − In the first postnatal day: 80–100 mL/kg/day− After the first postnatal week: 135–150 mL/kg/day [32–34]
Provide adequate incubator humidity − In the first postnatal week: 60–70% [37]
Maintain adequate temperature
− Abdominal skin: 36.0–36.5 ◦C
− Inspired air temperature (hood, CPAP, or ventilator):
34.0–41.0 ◦C, relative humidity of 100%
[38,39]
Optimize early parenteral energy intake − In the first postnatal week: 80–100 kcal/kg/day− After the first postnatal week: 120–150 kcal/kg/day [44,78]
Optimize early parenteral amino acid intake
− Start with 1.5–2 g/kg/day after birth
− Increase to 3.5 g/kg/day from the first
48–72 postnatal hours
[79]
Optimize early parenteral fat intake
− Start with 1.0–2.0 g/kg/day within the first
postnatal day
− Increase by 0.5–1.0 g/kg/day up to a maximum of
4.0 g/kg/day at 72–96 postnatal hours
[80]
Provide adequate intravenous glucose − Limit the rate to 12 mg/kg/min (ideal limit:
8.3 mg/kg/min)
[33]
Optimize early parenteral calcium and
phosphorus intake
− In the first postnatal week: parenteral Ca
32–80 mg/kg/day and P 31–62 mg/kg/day
− After the first postnatal week: parenteral Ca
100–140 mg/kg/day and P 77–108 mg/kg/day
− Parenteral Ca/P ratio: 1.3 (mass) or 1 (molar)
[86]
Provide adequate intravenous lipid
soluble vitamins
− Vitamin A (retinol) 227–455 µg/kg/day or
700–1500 IU/kg/day
− Vitamin E (α-tocopherol) 2.8–3.5 IU/kg/day
[90]
Provide adequate intravenous trace elements − Particularly zinc 400–500 µg/kg/day [91]
Initiate early enteral feeding
− Initiate minimal enteral feeding (12–24 mL/kg/day)
prior to 3rd postnatal day
− Use preferably mother’s own milk or donor human
milk as second choice
[101,106,125]
7.2.4. Feeding Methods
Tube feeding for a long period of time may be required in very preterm infants with
DBP [27]. In these infants, several repeated negative stimuli contribute to difficulties in feed-
ing by mouth, including prolonged orotracheal intubation, hypoxic episodes, tachypnea,
altered gastrointestinal motility associated with the use of methylxanthines, and irritability
related with neurological status [27]. In addition, the prevalence of gastroesophageal reflux
(GER) is high in BPD infants, particularly acid reflux in ELBW infants [128,129]. Episodes of
acid reflux have been implicated in the worsening of lung disease, and the occurrence
and frequency of symptoms in BPD, depending on the most proximal esophageal extent
of the acid reflux and acid clearance [128]. An observational cohort study monitored
esophageal pH impedance in symptomatic infants of less than 33 weeks’ gestation with
and without BPD [130]. Infants with BBP, compared with those without BPD, had more
frequent pH-only events (median number 21 vs. 9) and a higher symptom sensitivity
index for pH-only events (9% vs. 4.9%). These findings may be explained by impaired
esophageal motility and a peculiar autonomic nervous system response pattern in infants
with BPD [130]. Considering the increasing concerns over the safety of antiacid drugs
in preterm infants, pharmacologic treatment for GER should be initiated only after the
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demonstration of pathological pH-MII monitoring [130]. Transpyloric feedings have been
suggested to reduce episodes of apnea and bradycardia in GER [131]. However, a trial in
very preterm infants with severe BPD did not demonstrate the advantage of transpyloric
feedings compared with gastric feedings in relation to the frequency of hypoxemia [132].
In more severe cases of GER, gastrostomy tube placement along with fundoplication may
be necessary [27].
Table 2. Nutritional management in infants with established BPD, either in the hospital or after discharge.
Intervention Reference
Fluid restriction Less than 150 mL/kg/dayIdeally, up to 135 mL/kg/day [32–34]
Optimize enteral energy intake Ideally, 120–150 kcal/kg/day [33,44]
Optimize enteral protein intake − <1000 g body weight: 4.0–4.5 g/kg/day− 1000–1800 g body weight: 3.5–4.0 g/kg/day [92]
Optimize enteral lipid intake
− Total lipid intake 4.8–6.6 g/kg/day
− Arachidonic acid 12–30 mg/kg/day
− Docosahexaenoic acid 18–42 mg/kg/day
[92]
Optimize enteral calcium and
phosphate intake
− Ca 120–140 mg/kg/day *; 150–220 mg/kg/day **
− P 60–90 mg/kg/day *; 75–140 mg/kg/day **
− Ca/P ratio: 2 (mass) *
[92]
[97]
Optimize sodium intake if diuretics are used − Provide sodium supplement to maintain serum
Na >135 mEq/L
[12]
Optimize enteral vitamin A intake 400–1000 µg/kg/day or 1320–3300 IU/kg/day [92]
Optimize enteral vitamin E
(α-tocopherol) intake 2.2–11 mg/kg/day [92]
Supplemental iron 4 mg/kg/day, from 4–8 postnatal weeks up to12 months of life [33]
Note: * [92]; ** [97].
Deglutition apnea during non-nutritive suckling has been evaluated in relation to
swallowing and breathing in infants with low risk of BPD and at risk of developing
BPD [133]. No significant differences were noted between groups in relation to the swallow–
breath interaction and the likelihood of respiration incidents [133]. In addition, no effect
on these parameters was found with an individualized intervention by a speech-language
specialist [133].
7.2.5. Tracheostomy
The decision about whether and when to place a tracheostomy in infants with severe
BPD dependent on a prolonged ventilator is difficult for both families and clinicians [11].
In these cases, tracheostomy has the advantage of reducing agitation and sedative medica-
tion and allowing a better parent–child interaction [11].
In a retrospective cohort study including 72 very preterm infants with BPD who
required tracheostomy, significant improvements in weight and length were recorded by
four weeks after tracheostomy placement [134]. In particular, the median length z-score
increased from −3.07 to −1.95, curiously associated with a significant reduction in the
mean energy intake, from 108.9 to 93.8 kcal/kg/day [134].
7.3. Nutrition after Discharge
In infants with BPD, discharge should be carefully organized based on a plan decided
in agreement with a multidisciplinary team, ideally consisting of a neonatologist, a neonatal
nurse, a pulmonologist, and a nutritionist [12,14].
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Infants with BPD often have difficulty in achieving coordinated suckle feeding,
which initially limits breast feeding or the use of a bottle [135,136]. The low feeding
efficiency is due to low sucking pressure and sucking frequency, short sucking duration,
gagging, high respiratory rate, an excessive decrease in oxygen saturation, and long deglu-
tition apnea [27,119]. As mentioned before, infants with BPD have a higher incidence of
GER, which increases the risk of aspiration, pneumonia, apnea, and failure to thrive [119].
In a cross-sectional study of 4–8-year-old children who had been born prematurely
and suffered BPD, it was concluded that undernutrition at the age of two years was the
only factor associated with the risk of developing distension of the airway [120].
As BPD infants do not tolerate high fluid intake, feedings highly concentrated in
energy and nutrients should be offered after discharge, using either fortified breastmilk
or enriched formula [119]. Investigation is needed to clarify whether BPD infants have
similar nutritional advantages when fed fortified breastmilk, as described in preterm
infants without BPD [109,137].
When the growth of exclusively breastfed BPD infants is poor, postdischarge formulas
may be an option [138,139], alternating with breastfeeding or in place of breastfeeding.
Postdischarge formulas are enriched with energy and nutrients designed for short- to
medium-term use in healthy preterm infants after discharge, and their energy and nutrient
content is in between that of preterm formulas and term formulas [136].
If poor growth persists despite using a postdischarge formula, this may be replaced
with a preterm formula, providing in the same volume (100 mL) more energy (circa 80
vs. 73 kcal), protein (circa 2.4 vs. 1.9 g), calcium (circa 140 vs. 80 mg), and phosphorus
(circa 75 vs. 50 mg) [136,139]. In a trial, BPD infants fed preterm formula attained signifi-
cantly greater length, bone mineral content, and lean mass at three months corrected age
than those fed a term formula [122].
8. Monitoring
8.1. While in the Hospital
Anthropometry should be used to monitor the growth of BPD infants, as recom-
mended for preterm infants under intensive care [140] (Table 3). Body weight should be
measured daily and length and head circumference weekly, using correct methods and
appropriate charts to interpret the measurements [140].
Accurate fluid management is crucial for infants at risk of developing BPD. Therefore,
a tool sensitive enough to detect sudden weight changes will indicate inappropriate extra-
cellular water changes rather than changes in body lean or fat mass [140,141]. Charts that
do not take into account the initial weight loss in the result of physiological reduction of
extracellular volume, such as the Fenton 2013 charts [142], are inappropriate for moni-
toring short-term postnatal weight changes [143]. A comprehensive longitudinal study
provided new charts to monitor body weight [144]. Based on this study, a growth calculator
that displays graphically in which percentile the current weight is plotted was devel-
oped [141]. This free-access online tool (https://www.growthcalculator.org/) (accessed on
21 April 2021) is sensitive to accurately detect weight changes, exhibiting the target weight
and the deviation of the current weight.
After the initial physiological weight loss, weight gain velocity (in g/kg/day) is
more sensitive for identifying changes in growth than examining the weight plotted on
growth curves [144,145]. For a precise calculation of weight gain velocity, the optimum
period seems to be a time interval of at least 5–7 days [146]. Body weight gain rates of
15–20 g/kg/day are considered adequate for infants born at 23–36 weeks of gestation [48].
Length and head circumference growth velocities provide sensitive measurements
of linear and head growth: rates of 0.9–1.1 cm/week and 0.9–1.0 cm/week, respectively,
are adequate for preterm infants, particularly for 23–30 weeks PMA [140,147].
Some biochemical markers are useful in the assessment of nutritional status and
should complement the anthropometric assessment (Table 3). In clinically stable preterm
infants, blood urea nitrogen (BUN) is useful to monitor the adequacy of enteral protein
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intake, and may guide the use of HM fortifiers and the addition of modular protein when
necessary [113,139]. A BUN value lower than 1.6 mmol/L (4.48 mg/dL) indicates insuffi-
cient protein intake [140,148]. In preterm infants, complete blood count with reticulocyte
count and serum ferritin levels should be regularly measured to monitor iron status [27,140].
Low phosphorus and high alkaline phosphate serum levels are reasonable early indica-
tors of metabolic bone disease of prematurity [139,149]. Regular measurements of serum
electrolytes are needed if diuretics are used [12,27]. In case of prolonged use of diuretics,
renal ultrasound is recommended for nephrocalcinosis screening [12].
Table 3. In-hospital monitoring of infants with BPD.
Parameter Reference
Body weight (daily)
− Body weight change: online calculator
(https://www.growthcalculator.org/) (accessed on
21 April 2021)
− Weight gain velocity; ideally 15–20 g/kg/day
[141]
[146]
Body length (weekly) Body length velocity: 0.9–1.1 cm/week [147]
Head circumference (weekly) Head circumference velocity: 0.9–1.0 cm/week [147]
Monitoring iron status Complete blood count with reticulocyte count, and serumferritin levels [140]
Monitoring protein nutrition Blood urea nitrogen (BUN) [113]
Monitoring early metabolic bone disease Serum phosphorus and alkaline phosphate levels [149]
Monitoring electrolyte balance (diuretics use) Serum electrolytes [27]
8.2. After Discharge
Regular outpatient follow-up with a pediatrician and subspecialists is recommended,
based on anthropometry and biochemical markers [12] (Table 4).
Table 4. Monitoring infants with BPD after discharge.
Parameter Reference
Body weight, length, and head circumference
Intergrowth-21st standards: monitoring up to 64 weeks
postmenstrual age, for infants born at >26 and <37 weeks
of gestation
[150]
Monitoring iron status Complete blood count with reticulocyte count, and serumferritin levels [140]
Monitoring protein nutrition Blood urea nitrogen (BUN) [113]
Monitoring metabolic bone disease Serum phosphorus and alkaline phosphate levels [149]
Monitoring electrolyte balance (if diuretic use) Serum electrolytes [27]
Monitoring vitamins and trace elements
(if deficiency suspicion)
Serum levels of vitamin A, 25-hydroxy vitamin D, zinc,
and selenium [27]
Body weight, length, and head circumference should be evaluated on a regular ba-
sis [12]. The longitudinal Intergrowth-21st standards are more appropriate to interpret body
weight, length, and head circumference measurements up to 64 weeks PMA, for infants
born at more than 26 weeks and less than 37 weeks of gestation [139,150].
Particularly in infants fed unfortified breast milk, surveillance of iron deficiency
anemia, protein malnutrition, and metabolic bone disease is recommended. Thus, com-
plete blood count and serum levels of ferritin, BUN, calcium, phosphorus, magnesium,
and alkaline phosphate should be measured on a regular basis [12,27]. Regular moni-
toring of serum electrolytes and trace minerals is recommended if the infant remains on
diuretics [12,27].
Int. J. Environ. Res. Public Health 2021, 18, 6245 14 of 20
Serum levels of specific vitamins and trace elements, including vitamin A, 25-hydroxy
vitamin D, zinc, and selenium, should be determined if deficiency is suspected [27].
9. Conclusions
Nutrition plays a crucial role in lung growth and repair in infants with BPD. When pre-
scribing early nutritional support to preterm infants, protection of the lungs encompasses
avoidance of fluid overload. Ideally, these infants should receive a fluid intake not exceed-
ing 135–150 mL/kg/day. Providing an ideal energy intake of 120–150 kcal/kg/day in the
presence of this fluid restriction remains a challenge and is the main reason for poor growth
in DBP infants.
An adequate nutritional approach for preterm infants implies early aggressive par-
enteral nutrition while initiating trophic feeding and progressing to nutritive enteral nutri-
tion as soon as possible. To provide high energy and nutrient intakes in a low volume of
feedings, multinutrient fortification of the mother’s own milk or of donor milk is necessary.
When HM is insufficient, enriched formulas with a high density of energy and nutrients
are preferred.
Specialized nutritional techniques may be used to overcome gastroesophageal reflux
and poor coordination of suckling, which are common in infants with DBP. Tracheostomy
may result in nutritional advantages in infants requiring prolonged invasive ventilation.
Planning nutrition support after discharge requires a multidisciplinary approach for the
multiple clinical problems that these infants face. To monitor the nutritional intervention,
anthropometry and appropriate growth charts and specific biochemical markers should
be used.
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Abbreviations
BPD bronchopulmonary dysplasia
BUN blood urea nitrogen
DHA docosahexaenoic acid
DHM donor human milk
ELBW extremely low birth weight
ESPGHAN European Society for Paediatric Gastroenterology Hepatology and Nutrition
GER gastroesophageal reflux
HM human milk
IVFEs intravenous fat emulsions
LA linoleic acid
MCT medium-chain triglycerides
MOM mother’s own milk
PMA postmenstrual age
VLBW very low birth weight
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